Labcorp director Kerrii Anderson sells shares worth $130,000

Published 12/06/2025, 15:12
Labcorp director Kerrii Anderson sells shares worth $130,000

Labcorp Holdings Inc. (NYSE:LH), a prominent healthcare services provider with a market capitalization of $21.7 billion, saw Director Kerrii B. Anderson recently sell 500 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a price of $260.00 each, totaling $130,000. Following this transaction, Anderson holds 12,666 shares directly. The sale was conducted under a prearranged trading plan in accordance with Rule 10b5-1. The transaction comes as the stock trades near its 52-week high of $262.12, with InvestingPro data indicating overbought conditions. Despite this insider sale, analysts maintain a bullish outlook with a consensus target suggesting further upside potential. For deeper insights into insider trading patterns and 8 additional exclusive ProTips, explore InvestingPro’s comprehensive analysis.

In other recent news, Labcorp Holdings Inc. reported its Q1 2025 earnings, showing a revenue increase to $3.3 billion, up 5.3% year-over-year, but missing the forecasted $3.41 billion. The company achieved an adjusted EPS of $3.84, slightly surpassing the expected $3.78. Morgan Stanley (NYSE:MS) raised Labcorp’s stock price target to $283.00, maintaining an Overweight rating, citing durable demand and growth prospects. Similarly, Mizuho (NYSE:MFG) Securities lifted its price target to $274, keeping an Outperform rating, reflecting confidence in the company’s earnings visibility. Labcorp shareholders recently approved the 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan, aligning employee and shareholder interests. Additionally, Labcorp announced new product launches, including LabCorp Plasma Complete and genetic risk panel tests, as part of its strategic focus on high-growth areas. These developments come as Labcorp continues to navigate a challenging macroeconomic environment, maintaining a stable outlook with ongoing strategic partnerships and innovation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.